El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

advancesadv2020004136.pdf (1.22 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2021-09-13

Llicència de publicació

cc by-nc-nd (c) Oñate, Guadalupe et al, 2021
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/183760

Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1182/bloodadvances.2020004136

Resum

The negative prognostic impact of internal tandem duplication of FLT3 (FLT3-ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML-NPM1) is restricted to those with a higher FLT3-ITD allelic ratio (FLT3(high); >= 0.5) and considered negligible in those with a wild-type (FLT3WT)/low ITD ratio (FLT3low). Because the comutation of DNMT3A (DNMT3A(mut)) has been suggested to negatively influence prognosis in AMLNPM1, we analyzed the impact of DNMT3A(mut) in FLT3-ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML-NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3A(mut) status did not have a prognostic impact, with comparable overall survival (P = .2). Prognostic stratification established by FLT3-ITD (FLT3WT = FLT3low > FLT3(high)) was independent of DNMT3A(mut) status. Measurable residual disease (MRD) based on NPM1 quantitative polymerase chain reaction was available for 94 patients. DNMT3A(mut) was associated with a higher number of mutated NPM1 transcripts after induction (P = .012) and first consolidation (C1; P < .001). All DNMT3A(mut) patients were MRD+ after C1 (P < .001) and exhibited significant MRD persistence after C2 and C3 (MRD+ vs MRD-; P = .027 and P = .001, respectively). Finally, DNMT3A(mut) patients exhibited a trend toward greater risk of molecular relapse (P = .054). In conclusion, DNMT3A(mut) did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1 despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention.

Matèries

Leucèmia mieloide, Enzims

Matèries (anglès)

Myeloid leukemia, Enzymes

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

OÑATE, Guadalupe, BATALLER, Alex, GARRIDO, Ana, HOYOS COLELL, Montserrat, ARNAN, Montserrat, VIVES, Susana, COLL, Rosa, TORMO, Mar, SAMPOL, Antonia, ESCODA, Lourdes, SALAMERO, Olga, GARCIA, Antoni, BARGAY, Joan, ALJARILLA, Alba, NOMDEDEU, Josep f., ESTEVE, Jordi, SIERRA, Jorge, PRATCORONA, Marta. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. _Blood Advances_. 2021. Vol.  vol 6, núm. num 3, pàgs. 882-890. [consulta: 26 de desembre de 2025]. ISSN: 2473-9537. [Disponible a: https://hdl.handle.net/2445/183760]

Exportar metadades

JSON - METS

Compartir registre